SVB Leerink analyst Jonathan Chang maintains Macrogenics (NASDAQ:MGNX) with a Outperform and lowers the price target from $40 to $23.
SVB Leerink Maintains Outperform on Macrogenics, Lowers Price Target to $23
SVB Leerink analyst Jonathan Chang maintains Macrogenics (NASDAQ:MGNX) with a Outperform and lowers the price target from $40 to $23.
Related Posts
Franchise Group To Avail Loan From Apollo For Kohl’s Buyout: New York Post
Franchise Group Inc (NASDAQ:FRG) is considering taking more than $2 billion in loan from Apollo Global Management, Inc. (NYSE:APO) to acquire Kohl’s…
RadNet Q2 EPS $0.15 Beats $0.07 Estimate, Sales $354.40M Beat $348.94M Estimate
RadNet (NASDAQ:RDNT) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.07 by 114.29 percent. This is a 44.44 percent decrease over earnings of $0.27 per share from the same
Here’s How Much $100 Invested In Carlisle Companies 15 Years Ago Would Be Worth Today
Carlisle Companies (NYSE:CSL) has outperformed the market over the past 90 days by 7.09%, generating a 7.22% return for its investors over the time period. Now, given this information, it may seem like price appreciation alone is the best way to have made money on this stock, that's not actually the case.